by Jörg Schäfer, NMI Naturwissenschaftliches und Medizinisches Institut in Reutlingen Example ICC images of marker expression in iPSC (left) and NPC (right) obtained by high-content microscopy. Credit: BMC Psychiatry (2024). DOI: 10.1186/s12888-024-06127-x Up to now, schizophrenia has mainly been treated symptomatically, as little is known about the exact underlying processes. Researchers at the NMI Natural and Medical...
Tag: <span>Schizophrenia</span>
Post
Genetic risk for schizophrenia linked to a malformed skull
by St. Jude Children’s Research Hospital Research from the Zakharenko lab, St. Jude Department of Developmental Neurobiology published in Nature Communications revealed a gene deleted in 22q11.2 deletion syndrome results in malformed regions of the cerebellum, but the defect is a result of a local skull deformity. Pictured: first author on the paper Tae-Yeon Eom, PhD....
Post
Intermittent theta burst stimulation found to more effective for treating schizophrenia symptoms than other approaches
by Fujita Health University In a study published in JAMA Network Open, researchers from Fujita Health University, Japan conducted a systematic review and network meta-analysis using published data and verify the efficacy and safety of TBS protocols for schizophrenia. Credit: Public Relations Department, Fujita Health University, Japan Schizophrenia, which is characterized by positive symptoms (e.g., hallucinations and...
Post
Brain plasticity expert Peter Falkai discusses new pathways for treating schizophrenia
Max Planck Institute director Prof. Peter Falkai shares groundbreaking research insights in exclusive Genomic Press InterviewReports and Proceedings Genomic Press image: Peter Falkai, MD, PhD, Munich University Hospital, Germanyview more Credit: Peter Falkai, MD, PhD MUNICH, Germany, 19 November 2024 – In a comprehensive Genomic Press Interview, distinguished psychiatrist Professor Peter Falkai suggests promising new directions...
Post
FDA approves Cobenfy for adults with schizophrenia
by Lori Solomon The U.S. Food and Drug Administration has approved Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults. The oral medication represents the first new class of medicine in several decades and selectively targets M1 and M4 receptors in the brain, without blocking D2 receptors. The approval is...
Post
Psychedelic use linked to increased risk of schizophrenia, study finds
Peer-Reviewed Publication Institute for Clinical Evaluative Sciences image: Infographic: Myran et al. JAMA Psych. 2024view more Credit: ICES Ottawa, ON, November 13, 2024 – Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, according to a new study from researchers at ICES, The Ottawa Hospital, University of Ottawa’s Department of Family...
Post
Scientists may have found the reason why people with schizophrenia hear voices
Insights from new research could help expand treatment options beyond drugs Schizophrenia is a poorly understood illness, but scientists now have greater insight into one of the disorder’s hallmarks, auditory hallucinations, thanks to new research published Thursday. People with schizophrenia often “hear” voices and sounds even when there are none — up to 80% of...
Post
How does schizophrenia affect smell?
Scientists believe schizophrenia may affect a person’s sense of smell or cause them to smell things that are not there, but not all studies into schizophrenia and smell support this. Schizophrenia is a mental health condition that affects how a person thinks, feels, and behaves. The condition may also affect a person’s sense of smell...
Post
IS A NEW SCHIZOPHRENIA DRUG REALLY A GAME CHANGER?
A new drug is being hailed as a breakthrough for the 2.8 million American adults (among 24 million people worldwide) who battle schizophrenia. The US Food & Drug Administration (FDA) has greenlit Bristol Myers Squibb’s Cobenfy, reportedly making it the first major new treatment for the disorder in 70 years. Unlike other antipsychotic drugs, Cobenfy appears to...
Post
Scientists may have found the reason why people with schizophrenia hear voices
People with schizophrenia often “hear” voices and sounds even when there are none — up to 80% of people with the mental illness have auditory hallucinations. Scientists have theorized that this happens when a person with schizophrenia struggles to recognize inner speech as self-generated. But nobody had been able to fully explain the mechanisms behind this...